END - VT Cohort Study

Status Recruiting

Clinical Trial Summary

Ventricular tachycardia (VT) is a life-threatening cardiac rhythm disturbance which leads to sudden cardiac death (SCD), ventricular fibrillation, electrical storm, hemodynamic collapse, and syncope. VT patients with cardiomyopathy (diseased/scarred cardiac muscle) have the highest risk of SCD (<1-4%) and recurrent VTs (15-35%). Although an implantable cardiac defibrillator (ICD) is the most effective treatment option to prevent SCD, it does not eliminate it. Without VT prevention, recurrent VT and ICD shocks may increase the risk of heart failure and death. The primary objective is to determine the optimal treatment strategy to maximize event-free survival among cardiomyopathy patients with ventricular tachycardia (VT) by the creation of a prospective, multicenter, longitudinal cohort. Also, the investigators will evaluate the epidemiology of VT, adherence to guidelines, safety, effectiveness, and cost-effectiveness of current treatment options for secondary prevention of VT in the real-world Canadian VT population.

Clinical Trial Description

The END-VT study is a multicenter, prospective, longitudinal real-world cohort study of patients with cardiomyopathy-related VT. Patients with ischemic and non-ischemic cardiomyopathy are followed from their first VT event till at least 3 years of follow-up or death, whichever is first. Outcomes of VT events are captured by ICD remote monitoring and are adjudicated by experienced clinical investigators blinded to the center and treatments. The primary objective of END-VT is to determine the optimal treatment strategy to maximize event-free survival among cardiomyopathy patients with VT. The investigator will also assess the real-world burden of disease, treatment challenges, adherence to guidelines, sex differences, and safety, effectiveness, and cost-effectiveness of VT treatments. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05835791
Study type	Observational [Patient Registry]
Source	Nova Scotia Health Authority
Contact	John L Sapp, MD, FRCPC
Phone	902-473-4272
Email	john.sapp@nshealth.ca
Status	Recruiting
Phase
Start date	January 12, 2024
Completion date	April 30, 2029

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03453645` - Modification of Rhythmic Risk Assessment by Ventricular Tachycardia Ablation
Completed	`NCT05791032` - Sub Chronic Evaluation for ATP With an Extravascular Placed ICD Lead (STEP ICD) Study	N/A
Completed	`NCT05970120` - A Study of Intracardiac Ultrasound With the NUVISION NAV Ultrasound Catheter	N/A
Completed	`NCT04011631` - Evaluation of the iD-SystemTM, One-Handed Disposable Internal Defibrillation System.	N/A
Recruiting	`NCT03536052` - Ablation at Virtual-hEart pRedicted Targets for VT	N/A
Not yet recruiting	`NCT06063811` - Ventricular Tachycardia Ablation in LVAD Patients
Enrolling by invitation	`NCT02962076` - Study of Cardiac PET/CT Imaging to Guide Ablation Treatment of Ventricular Tachycardia	Early Phase 1
Not yet recruiting	`NCT02784912` - Biomarkers in Risk Stratification of Sustainted Ventricular Tachycardia or Electrical Storm After Ablation	N/A
Completed	`NCT01791543` - Intramural Needle Ablation for Ablation of Recurrent Ventricular Tachycardia	N/A
Terminated	`NCT02891863` - Low Energy Therapy to Convert Ventricular Tachycardias	Phase 0
Terminated	`NCT01546207` - Stepwise Approach To sUbstrate Modification for Ventricular Tachycardia	N/A
Completed	`NCT01294267` - Percutaneous Hemodynamic Support With Impella 2.5 During Scar-related Ventricular Tachycardia Ablation	N/A
Terminated	`NCT00383799` - Iv Amiodarone Versus Iv Procainamide to Treat Haemodynamically Well Tolerated Ventricular Tachycardia	Phase 4
Completed	`NCT04884100` - enHEART - Exploring Full Content of Optical Signals to Enhance Cardiac Arrhythmia Screening	N/A
Completed	`NCT04642963` - Stereotactic Management of Arrhythmia - Radiosurgery in Treatment of Ventricular Tachycardia	N/A
Recruiting	`NCT05377216` - Characterization of Cardiac Electrophysiological Effects of Autonomic Neuromodulation	Early Phase 1
Not yet recruiting	`NCT04990089` - VIVO European Observational Registry
Completed	`NCT04065893` - Impact of Catheter Ablation of Ventricular Arrhythmias on Suboptimal Biventricular Pacing in Cardiac Resynchronization Therapy
Recruiting	`NCT03631303` - Post-Extrasystolic Potentiation as a Predictor of Ventricular Arrhythmias
Recruiting	`NCT03611465` - Creation of a Pace-mapping Atlas on Healthy and Pathological Hearts	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

END - VT Cohort Study — END VT

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms